STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1326 by analyst upside · 2026-08-13
PVLA
Palvella Therapeutics, Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+48.7%
implied upside to consensus target
Current Price $155.07
Consensus Target $230.53
Bull Target $270.0
Bear Target $205.0
Analysts Covering 15
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
15
Hold
0
Sell
0
52-Week Low $41.71
52-Week High $161.38
YTD Return +54.6%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-4.85
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $41.71
52-Week High $161.38
Current Price $155.07
Bear Target $205.0
Bull Target $270.0
● Now $155.07 ● Target $230.53
TRADING DATA
Avg Volume 254K
YTD Return +54.6%
Analyst Count 15
Consensus Buy
Upside to Target +48.7%
Last Updated 2026-08-13

ANALYST SUMMARY

Palvella Therapeutics, Inc. (PVLA) is currently trading at $155.07 with a Wall Street consensus price target of $230.53, implying potential upside of 48.7% over the next 12 months. 15 analysts currently cover PVLA, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $270.0, while the most cautious has a target of $205.0.

PVLA operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 54.6% year-to-date and is currently trading near the upper end of its 52-week range of $41.71 – $161.38.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PVLA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Stephens & Co. reit
Overweight → Overweight 2026-05-21 Building track record
Chardan Capital - Reiterated
Buy → Buy 2026-05-21 33% win rate (6 calls)
Stephens & Co. ● Initiated
Overweight 2026-05-12 Building track record
Chardan Capital - Reiterated
Buy → Buy 2026-03-31 33% win rate (6 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-03-24 31% win rate (48 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-03-16 33% win rate (6 calls)
Mizuho - Reiterated
Outperform → Outperform 2026-02-25 Building track record
BTIG - Reiterated
Buy → Buy 2026-02-25 38% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
70
out of 100
Coverage depth
21/30
Consensus clarity
22/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →